InflaRx

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell InflaRx and other ETFs, options, and stocks.

About IFRX

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab.

CEO

Niels Christoph Riedemann

CEONiels Christoph Riedemann

Employees

Employees74

Headquarters

Jena, Thueringen

HeadquartersJena, Thueringen

Founded

2007

Founded2007

Employees

Employees74

IFRX Key Statistics

Market cap

54.38M

Market cap54.38M

Price-Earnings ratio

-0.76

Price-Earnings ratio-0.76

Dividend yield

—

Dividend yield—

Average volume

367.09K

Average volume367.09K

High today

$0.793

High today$0.793

Low today

$0.771

Low today$0.771

Open price

$0.78

Open price$0.78

Volume

1.90K

Volume1.90K

52 Week high

$2.82

52 Week high$2.82

52 Week low

$0.7113

52 Week low$0.7113

Analyst ratings

88%

of 8 ratings

Buy

87.5%

Hold

12.5%

Sell

People also own

Based on the portfolios of people who own IFRX. This list is generated using Robinhood data, and it’s not a recommendation.